Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Biologic response modifiers and urologic malignancies.

J Fleischmann1

  • 1Case Western Reserve University School of Medicine, Cleveland, Ohio.

The Surgical Clinics of North America
|October 1, 1988
PubMed
Summary

Biologic response modifiers show promise for treating bladder cancer and urinary tract infections. Measuring these agents in urine may guide therapy for better patient outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prevalence and Treatment of Chronic Lymphocytic Leukaemia (Cll) In Germany: An Analysis of Sickness Funds.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2016
Same author

Knee and hip joint biomechanics are gender-specific in runners with high running mileage.

International journal of sports medicine·2013
Same author

Prevalence of smell loss in Parkinson's disease--a multicenter study.

Parkinsonism & related disorders·2009
Same author

Polyadenylation of ribosomal RNA by Candida albicans.

Gene·2001
Same author

Expression of deoxyuridine triphosphatase (dUTPase) in colorectal tumours.

International journal of cancer·1999
Same author

Air on radiography of perineal necrotizing fasciitis indicates testis involvement.

The Journal of urology·1999

Area of Science:

  • Immunology and Oncology
  • Urology

Background:

  • Biologic response modifiers (BRMs) are emerging immunotherapeutic agents.
  • BRMs like interferon have shown moderate success in B-cell malignancies.
  • Their efficacy in advanced genitourinary malignancies is limited.

Purpose of the Study:

  • To explore the potential utility of measuring urinary biologic response modifiers.
  • To investigate BRMs for directing intravesical BCG therapy in superficial bladder cancer.
  • To assess BRMs for guiding prophylactic antibiotic use in urinary tract infections.

Main Methods:

  • Analysis of biologic response modifiers in urine samples.
  • Correlation of BRM levels with treatment response.
  • Evaluation of BRM-guided therapy protocols.

Main Results:

  • Urinary BRM measurement may inform intravesical BCG therapy for bladder cancer.
  • BRM levels could guide prophylactic antibiotic selection for UTIs.
  • Further research is needed to validate these findings.

Conclusions:

  • Urinary biologic response modifiers hold potential as biomarkers.
  • BRM measurement could personalize treatment strategies in urologic conditions.
  • This approach may improve therapeutic efficacy and reduce antibiotic resistance.

Related Experiment Videos